Face to face with oral isotretinoin: a closer look at the spectrum of therapeutic outcomes and why some patients need repeated courses - PubMed (original) (raw)
Face to face with oral isotretinoin: a closer look at the spectrum of therapeutic outcomes and why some patients need repeated courses
James Q Del Rosso. J Clin Aesthet Dermatol. 2012 Nov.
Abstract
Oral isotretinoin, available in the United States for four decades, has been used for the treatment of recalcitrant nodular and deep inflammatory acne vulgaris. This drug revolutionized the management of patients affected by severe inflammatory disease due to its ability to markedly induce acne clearance coupled with prolonged durations of remission after completion of a course of therapy, usually over approximately five months. Over time, it has become recognized that prolonged remission correlates with achieving a threshold cumulative exposure range of approximately 120 to 150 mg/kg of oral isotretinoin. Lesser exposures have demonstrated a higher risk of earlier recurrence of acne vulgaris and a greater likelihood that the patient will require retreatment. As the oral bioavailability of oral isotretinoin is variable, and highly dependent on administration with food, it is very conceivable that earlier relapse may occur if patients have often ingested oral isotretinoin on an empty stomach, thus leading to lesser actual cumulative drug exposure despite the daily dose administered. This article provides an overview on the dosing of oral isotretinoin, reported data on factors that influence relapse after oral isotretinoin therapy, and the potential impact of coadministration with food.
Similar articles
- Rationale for Use of Micronized Isotretinoin for Treatment of Acne Vulgaris: Practical Considerations and Therapeutic Advantages.
Del Rosso JQ. Del Rosso JQ. J Clin Aesthet Dermatol. 2023 Sep;16(9):20-24. J Clin Aesthet Dermatol. 2023. PMID: 37720199 Free PMC article. Review. - Evaluation of Evidence for Acne Remission With Oral Isotretinoin Cumulative Dosing of 120-150 mg/kg.
Tan J, Knezevic S, Boyal S, Waterman B, Janik T. Tan J, et al. J Cutan Med Surg. 2016 Jan;20(1):13-20. doi: 10.1177/1203475415595776. Epub 2015 Jul 17. J Cutan Med Surg. 2016. PMID: 26187395 Review. - High-dose isotretinoin treatment and the rate of retrial, relapse, and adverse effects in patients with acne vulgaris.
Blasiak RC, Stamey CR, Burkhart CN, Lugo-Somolinos A, Morrell DS. Blasiak RC, et al. JAMA Dermatol. 2013 Dec;149(12):1392-8. doi: 10.1001/jamadermatol.2013.6746. JAMA Dermatol. 2013. PMID: 24173086 - High-dose isotretinoin in acne vulgaris: improved treatment outcomes and quality of life.
Cyrulnik AA, Viola KV, Gewirtzman AJ, Cohen SR. Cyrulnik AA, et al. Int J Dermatol. 2012 Sep;51(9):1123-30. doi: 10.1111/j.1365-4632.2011.05409.x. Int J Dermatol. 2012. PMID: 22909370 - Roaccutane treatment guidelines: results of an international survey.
Cunliffe WJ, van de Kerkhof PC, Caputo R, Cavicchini S, Cooper A, Fyrand OL, Gollnick H, Layton AM, Leyden JJ, Mascaró JM, Ortonne JP, Shalita A. Cunliffe WJ, et al. Dermatology. 1997;194(4):351-7. doi: 10.1159/000246134. Dermatology. 1997. PMID: 9252756 Clinical Trial.
Cited by
- Rationale for Use of Micronized Isotretinoin for Treatment of Acne Vulgaris: Practical Considerations and Therapeutic Advantages.
Del Rosso JQ. Del Rosso JQ. J Clin Aesthet Dermatol. 2023 Sep;16(9):20-24. J Clin Aesthet Dermatol. 2023. PMID: 37720199 Free PMC article. Review. - Drug repurposing of dermatologic medications to treat coronavirus disease 2019: Science or fiction?
Vassileva S, Mateeva V, Drenovska K. Vassileva S, et al. Clin Dermatol. 2021 May-Jun;39(3):430-445. doi: 10.1016/j.clindermatol.2021.01.020. Epub 2021 Feb 2. Clin Dermatol. 2021. PMID: 34518001 Free PMC article. - Lidose-Isotretinoin Administered Without Food Improves Quality of Life in Patients With Severe Recalcitrant Nodular Acne: An Open-Label, Single-Arm, Phase IV Study.
Zaenglein AL, Segal J, Darby C, Del Rosso JQ. Zaenglein AL, et al. J Clin Aesthet Dermatol. 2020 Sep;13(9):15-20. Epub 2020 Sep 1. J Clin Aesthet Dermatol. 2020. PMID: 33133336 Free PMC article. - Consensus on the use of oral isotretinoin in dermatology - Brazilian Society of Dermatology.
Bagatin E, Costa CS, Rocha MADD, Picosse FR, Kamamoto CSL, Pirmez R, Ianhez M, Miot HA. Bagatin E, et al. An Bras Dermatol. 2020 Nov-Dec;95 Suppl 1(Suppl 1):19-38. doi: 10.1016/j.abd.2020.09.001. Epub 2020 Oct 3. An Bras Dermatol. 2020. PMID: 33036809 Free PMC article.
References
- Patton TJ, Zirwas MJ, Wolverton SE. Systemic retinoids. In: Wolverton SE, editor. Comprehensive Dermatologic Drug Therapy. 2nd ed. Philadelpha: Saunders-Elsevier; 2007. pp. 275–300.
- Accutane [package insert]. Nutley, NJ: Hoffman-LaRoche, Inc. [Discontinued by manufacturer June 29, 2009; generic formulations available from other manufacturers].
- Claravis [package insert]. Montvale, NJ: Barr Laboratories; 2010.
- Gollnick H, Cunliffe W, Berson D, et al. Management of acne: a report from the Global Alliance to Improve Outcomes in Acne. J Am Acad Dermatol. 2003;49(1 Suppl):S1–S37. - PubMed
- Peck GL, Olsen TG, Yoder FW, et al. Prolonged remissions of cystic and conglobate acne with 13-cis-retinoic acid. N Engl J Med. 1979;300:329–333. - PubMed
LinkOut - more resources
Full Text Sources
Research Materials